<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003436</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066463</org_study_id>
    <secondary_id>MRC-LEUK-AML12CH</secondary_id>
    <secondary_id>EU-98010</secondary_id>
    <nct_id>NCT00003436</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia</brief_title>
  <official_title>Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with bone marrow transplantation may&#xD;
      allow doctors to give higher doses of chemotherapy and kill more cancer cells. It is not yet&#xD;
      known whether chemotherapy is more effective with or without bone marrow transplantation for&#xD;
      acute myeloid leukemia.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with or&#xD;
      without bone marrow transplantation in treating children who have acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare two induction schedules with respect to achievement and duration of remission,&#xD;
           survival, toxicity, and supportive care requirements in children with previously&#xD;
           untreated acute myeloid leukemia.&#xD;
&#xD;
        -  Compare 4 versus 5 courses of treatment in total (where the final course is either&#xD;
           chemotherapy or bone marrow transplantation) with respect to remission duration, relapse&#xD;
           rates, deaths in remission, and overall survival in these patients.&#xD;
&#xD;
        -  Compare the value of allogeneic bone marrow transplantation versus conventional&#xD;
           chemotherapy with respect to remission duration, relapse rates, deaths in remission, and&#xD;
           overall survival in these patients.&#xD;
&#xD;
        -  Reduce toxicity without compromising survival by restricting the number of patients&#xD;
           receiving bone marrow transplant in this study.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are first randomized to one of two induction&#xD;
      treatment arms.&#xD;
&#xD;
        -  Induction Arm I: Patients receive 2 courses of cytarabine IV push every 12 hours on days&#xD;
           1-10 or 1-8 (20 or 16 doses); daunorubicin IV over 6 hours on days 1, 3, and 5; and&#xD;
           etoposide IV over 4 hours on days 1-5 (5 doses).&#xD;
&#xD;
        -  Induction Arm II: Patients receive 2 courses of mitoxantrone IV over 6 hours on days 1,&#xD;
           3, and 5; cytarabine IV push every 12 hours on days 1-10 or 1-8 (20 or 16 doses); and&#xD;
           etoposide IV over 4 hours on days 1-5 (5 doses).&#xD;
&#xD;
      Patients with no CNS disease at diagnosis receive 3 courses of triple intrathecal therapy&#xD;
      (methotrexate, cytarabine, and hydrocortisone), one after each of the first 3 courses of&#xD;
      chemotherapy. Patients with CNS disease receive at least 6 courses of intrathecal therapy (2&#xD;
      courses per week), then monthly courses until the final course of chemotherapy is complete.&#xD;
&#xD;
      Patients in complete response after induction course 2 continue on this study. Patients not&#xD;
      in complete response after induction course 2 are taken off study and are eligible for the&#xD;
      current Medical Research Council (MRC) refractory/relapse study or another therapy.&#xD;
&#xD;
      Course 3: All patients continuing on this study receive amsacrine IV over 1 hour daily on&#xD;
      days 1-5, cytarabine continuous IV infusion daily on days 1-5, and etoposide IV over 4 hours&#xD;
      on days 1-5 as course 3. After course 3, patients are assigned to two risk groups: good risk&#xD;
      patients, and standard and poor risk patients.&#xD;
&#xD;
      Standard and poor risk patients with no matched sibling donor and good risk patients are then&#xD;
      further randomized to consolidation in arms I or II.&#xD;
&#xD;
        -  Arm I: Patients receive mitoxantrone IV over 6 hours on days 1-5 and cytarabine IV over&#xD;
           2 hours every 12 hours on days 1-3 (4 courses of chemotherapy total).&#xD;
&#xD;
        -  Arm II: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 2, 8, and&#xD;
           9, and asparaginase subcutaneous infusion 3 hours after completion of the last&#xD;
           cytarabine doses on days 2 and 9, followed by a course of mitoxantrone and cytarabine as&#xD;
           in arm I (5 courses of chemotherapy total).&#xD;
&#xD;
      Standard and poor risk children with matched sibling donor are randomized to arms III or IV.&#xD;
&#xD;
        -  Arm III: Patients receive no consolidation treatment (3 courses of chemotherapy total)&#xD;
           plus bone marrow transplantation.&#xD;
&#xD;
        -  Arm IV: Patients receive cytarabine and asparaginase as in arm II (4 courses of&#xD;
           chemotherapy total) plus bone marrow transplantation.&#xD;
&#xD;
      Patients are followed for at least 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 2,000 patients will be accrued into this study over 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amsacrine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Histologically confirmed de novo or secondary acute myeloid leukemia (AML)&#xD;
&#xD;
               -  Aggressive myelodysplastic syndromes (refractory anemia with excess blasts (RAEB)&#xD;
                  and RAEB in transformation) for which intensive AML therapy is considered&#xD;
                  appropriate&#xD;
&#xD;
               -  Acute promyelocytic leukemia (should also be entered into protocol MRC-ATRA)&#xD;
&#xD;
          -  No chronic myeloid leukemia in blast transformation&#xD;
&#xD;
          -  Must be considered suitable for intensive chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 16&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent active malignancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for leukemia&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim O.B. Eden, MB, BS, FRCPE, FRCP, FRCPCH, F</last_name>
    <role>Study Chair</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christie Hospital N.H.S. Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005 Dec;19(12):2130-8. doi: 10.1038/sj.leu.2403924.</citation>
    <PMID>16304572</PMID>
  </reference>
  <reference>
    <citation>Burnett AK, Hills RK, Goldstone AH, et al.: The impact of transplant in AML in 2nd CR: a prospective study of 741 in the MRC AML 10 and 12 trials. [Abstract] Blood 104 (11): A-620, 2004.</citation>
  </reference>
  <verification_date>December 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2003</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Amsacrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

